3 Undervalued Pharmaceuticals Stocks for Wednesday, May 28
Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, May 28 based on AAII’s Stock Grades.Tudor Pop
Stock Evaluator: Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. BHC
$6.89
-0.04
-0.58%
August 19, 2026 4:00:02 PM
EST
Volume: 2,503,242
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Commentary & Analysis
3 Undervalued Pharmaceuticals Stocks for Monday, March 24
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, March 24 based on AAII’s Stock Grades.Omar Beirat
Why Bausch Health Companies Inc.’s (BHC) Stock Is Up 10.29%
As of Thursday, February 20, Bausch Health Companies Inc.’s BHC share price has surged by 10.29%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Bausch Health Companies Inc.'s Q1 Earnings
Bausch Health Companies Inc.'s fiscal Q1 earnings report was released on Wednesday, February 19. Let's dive in to see if (BHC) missed or beat analyst's expectations.Omar Beirat
3 Undervalued Pharmaceuticals Stocks for Thursday, February 13
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, February 13 based on AAII’s Stock Grades.Tudor Pop
Financial Summary
| Share Statistics | BHC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,546.9 | $618.0 | 57% |
|
| Shares Out (Mil) | 378.1 | 44.8 | 85% |
|
| Institutional Ownership | 76.5% | 85.3% | 46% |
|
| Float (Mil) | 260.5 | 47.4 | 78% |
|
| Beta | 0.38 | 0.70 | 22% |
|
| Avg Daily Volume (000s) | 2,653 | 390 | 85% |
|
| Price Change (52-week) |
(12.6%) | 68.6% | 34% |
|
| Growth | BHC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.0% | 6.7% | 36% |
|
| Net Income (5yr) | 17.9% | (1.6%) | 69% |
|
| EPS (5yr) | 17.8% | 14.9% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.8% | (14.9%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 6 | |
| Current EPS | $1.192 | $4.466 | $4.193 | |
| Month Ago EPS | $1.281 | $4.421 | $4.217 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.243 | $4.326 | $4.059 | |
| Year/Year Chg | 75.3% | 963.3% | 703.1% | |
| Financials | BHC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10,853 | $291 | 85% |
|
| Net Income (TTM) (Mil) | ($1,098) | ($11) | 1% |
|
| EPS (TTM) | ($2.946) | ($0.700) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | $1,800 | ($6) | 87% |
|
| Net Cash Flow (TTM) (Mil) | $95 | $5 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $19,898 | $6 | 95% |
|
| Enterprise Value (Q1) (Mil) | $22,541 | $450 | 84% |
|
| Valuation | BHC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BHC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.8% | 67.0% | 82% |
|
| Net Margin | (10.1%) | (2.3%) | 21% |
|
| ROA | (4.2%) | (22.4%) | 31% |
|
| ROE | 86.6% | (20.2%) | 96% |
|
| Liabilities to Assets | 103.2% | 32.2% | 95% |
|
| F-Score | 6 | 3 | na |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lakonishok Screen
Factors: Value, Momentum
Identifying stocks trading at a discount to their industry norms but showing recent price strength and upward earnings revisions.
| Performance Since Inception: | 13.2% |
| +/- S&P 500: | +5.7 |
